Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more
Biogen Inc (BIIB) - Net Assets
Latest net assets as of December 2025: $18.26 Billion USD
Based on the latest financial reports, Biogen Inc (BIIB) has net assets worth $18.26 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($29.44 Billion) and total liabilities ($11.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $18.26 Billion |
| % of Total Assets | 62.01% |
| Annual Growth Rate | 14.73% |
| 5-Year Change | 66.58% |
| 10-Year Change | 50.53% |
| Growth Volatility | 55.96 |
Biogen Inc - Net Assets Trend (1985–2025)
This chart illustrates how Biogen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biogen Inc (1985–2025)
The table below shows the annual net assets of Biogen Inc from 1985 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $18.26 Billion | +9.22% |
| 2024-12-31 | $16.72 Billion | +12.95% |
| 2023-12-31 | $14.80 Billion | +10.54% |
| 2022-12-31 | $13.39 Billion | +22.16% |
| 2021-12-31 | $10.96 Billion | +2.56% |
| 2020-12-31 | $10.69 Billion | -19.89% |
| 2019-12-31 | $13.34 Billion | +2.36% |
| 2018-12-31 | $13.03 Billion | +3.44% |
| 2017-12-31 | $12.60 Billion | +3.87% |
| 2016-12-31 | $12.13 Billion | +29.37% |
| 2015-12-31 | $9.37 Billion | -13.31% |
| 2014-12-31 | $10.81 Billion | +25.44% |
| 2013-12-31 | $8.62 Billion | +23.80% |
| 2012-12-31 | $6.96 Billion | +8.35% |
| 2011-12-31 | $6.43 Billion | +17.94% |
| 2010-12-31 | $5.45 Billion | -12.97% |
| 2009-12-31 | $6.26 Billion | +7.85% |
| 2008-12-31 | $5.81 Billion | +4.91% |
| 2007-12-31 | $5.53 Billion | -22.59% |
| 2006-12-31 | $7.15 Billion | +3.53% |
| 2005-12-31 | $6.91 Billion | +1.16% |
| 2004-12-31 | $6.83 Billion | -3.22% |
| 2003-12-31 | $7.05 Billion | +342.10% |
| 2002-12-31 | $1.60 Billion | +18.28% |
| 2001-12-31 | $1.35 Billion | +21.91% |
| 2000-12-31 | $1.11 Billion | +12.95% |
| 1999-12-31 | $979.53 Million | +36.31% |
| 1998-12-31 | $718.61 Million | +34.00% |
| 1997-12-31 | $536.29 Million | +10.72% |
| 1996-12-31 | $484.37 Million | +26.47% |
| 1995-12-31 | $382.98 Million | +16.08% |
| 1994-12-31 | $329.93 Million | +1.46% |
| 1993-12-31 | $325.20 Million | +14.11% |
| 1992-12-31 | $285.00 Million | +19.25% |
| 1991-12-31 | $239.00 Million | +64.04% |
| 1990-12-31 | $145.70 Million | +4.67% |
| 1989-12-31 | $139.20 Million | +104.71% |
| 1988-12-31 | $68.00 Million | +0.15% |
| 1987-12-31 | $67.90 Million | -23.96% |
| 1986-12-31 | $89.30 Million | +19.23% |
| 1985-12-31 | $74.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2060650000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $20.55 Billion | 112.58% |
| Common Stock | $100.00K | 0.00% |
| Other Comprehensive Income | $-182.00 Million | -1.00% |
| Total Equity | $18.26 Billion | 100.00% |
Biogen Inc Competitors by Market Cap
The table below lists competitors of Biogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NEC Corporation
PINK:NIPNF
|
$26.89 Billion |
|
Shinhan Financial Group Co Ltd
NYSE:SHG
|
$27.03 Billion |
|
China Tower Corporation Limited
PINK:CTOWY
|
$27.10 Billion |
|
Imperial Brands PLC
OTCQX:IMBBY
|
$27.15 Billion |
|
Bajaj Finance Limited
NSE:BAJFINANCE
|
$26.81 Billion |
|
George Weston Limited
PINK:WNGRF
|
$26.81 Billion |
|
Fair Isaac Corporation
NYSE:FICO
|
$26.78 Billion |
|
Legrand SA
PINK:LGRVF
|
$26.77 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,716,000,000 to 18,256,800,000, a change of 1,540,800,000 (9.2%).
- Net income of 1,293,389,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 45,800,000.
- Other factors increased equity by 293,211,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.29 Billion | +7.08% |
| Other Comprehensive Income | $-45.80 Million | -0.25% |
| Other Changes | $293.21 Million | +1.61% |
| Total Change | $- | 9.22% |
Book Value vs Market Value Analysis
This analysis compares Biogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1078.44x to 1.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.17 | $183.26 | x |
| 1986-12-31 | $0.19 | $183.26 | x |
| 1987-12-31 | $0.13 | $183.26 | x |
| 1988-12-31 | $0.28 | $183.26 | x |
| 1989-12-31 | $0.36 | $183.26 | x |
| 1990-12-31 | $0.27 | $183.26 | x |
| 1991-12-31 | $0.35 | $183.26 | x |
| 1992-12-31 | $0.33 | $183.26 | x |
| 1993-12-31 | $0.40 | $183.26 | x |
| 1994-12-31 | $0.40 | $183.26 | x |
| 1995-12-31 | $0.54 | $183.26 | x |
| 1996-12-31 | $0.52 | $183.26 | x |
| 1997-12-31 | $0.58 | $183.26 | x |
| 1998-12-31 | $0.76 | $183.26 | x |
| 1999-12-31 | $2.07 | $183.26 | x |
| 2000-12-31 | $2.39 | $183.26 | x |
| 2001-12-31 | $3.38 | $183.26 | x |
| 2002-12-31 | $4.00 | $183.26 | x |
| 2003-12-31 | $21.14 | $183.26 | x |
| 2004-12-31 | $19.87 | $183.26 | x |
| 2005-12-31 | $19.95 | $183.26 | x |
| 2006-12-31 | $20.71 | $183.26 | x |
| 2007-12-31 | $17.29 | $183.26 | x |
| 2008-12-31 | $19.68 | $183.26 | x |
| 2009-12-31 | $21.49 | $183.26 | x |
| 2010-12-31 | $21.17 | $183.26 | x |
| 2011-12-31 | $26.23 | $183.26 | x |
| 2012-12-31 | $29.04 | $183.26 | x |
| 2013-12-31 | $36.17 | $183.26 | x |
| 2014-12-31 | $45.60 | $183.26 | x |
| 2015-12-31 | $40.55 | $183.26 | x |
| 2016-12-31 | $55.43 | $183.26 | x |
| 2017-12-31 | $59.15 | $183.26 | x |
| 2018-12-31 | $63.51 | $183.26 | x |
| 2019-12-31 | $71.20 | $183.26 | x |
| 2020-12-31 | $66.34 | $183.26 | x |
| 2021-12-31 | $72.84 | $183.26 | x |
| 2022-12-31 | $91.77 | $183.26 | x |
| 2023-12-31 | $101.64 | $183.26 | x |
| 2024-12-31 | $114.57 | $183.26 | x |
| 2025-12-31 | $124.45 | $183.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.08%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.18%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.61x
- Recent ROE (7.08%) is below the historical average (11.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | -25.50% | -126.49% | 0.18x | 1.15x | $-26.59 Million |
| 1986 | -31.58% | -440.63% | 0.06x | 1.13x | $-37.13 Million |
| 1987 | -33.28% | -262.79% | 0.11x | 1.19x | $-29.39 Million |
| 1988 | -1.76% | -5.83% | 0.25x | 1.19x | $-8.00 Million |
| 1989 | 2.30% | 11.23% | 0.20x | 1.04x | $-10.72 Million |
| 1990 | 5.28% | 15.37% | 0.32x | 1.09x | $-6.87 Million |
| 1991 | 3.01% | 11.73% | 0.24x | 1.06x | $-16.70 Million |
| 1992 | 13.44% | 30.96% | 0.40x | 1.09x | $9.80 Million |
| 1993 | 9.96% | 23.75% | 0.38x | 1.10x | $-120.00K |
| 1994 | -1.48% | -3.13% | 0.41x | 1.15x | $-37.89 Million |
| 1995 | 1.48% | 3.73% | 0.32x | 1.23x | $-32.64 Million |
| 1996 | 8.37% | 14.63% | 0.44x | 1.31x | $-7.91 Million |
| 1997 | 16.63% | 20.54% | 0.53x | 1.52x | $35.54 Million |
| 1998 | 19.30% | 24.87% | 0.60x | 1.29x | $66.84 Million |
| 1999 | 22.51% | 27.75% | 0.62x | 1.30x | $122.50 Million |
| 2000 | 30.15% | 36.04% | 0.65x | 1.29x | $222.94 Million |
| 2001 | 20.22% | 26.16% | 0.61x | 1.28x | $137.80 Million |
| 2002 | 9.28% | 36.64% | 0.20x | 1.26x | $-11.45 Million |
| 2003 | -12.41% | -470.14% | 0.02x | 1.35x | $-1.58 Billion |
| 2004 | 0.37% | 1.57% | 0.17x | 1.34x | $-657.55 Million |
| 2005 | 2.33% | 9.38% | 0.20x | 1.21x | $-529.88 Million |
| 2006 | 3.04% | 8.11% | 0.31x | 1.20x | $-497.47 Million |
| 2007 | 11.53% | 20.12% | 0.37x | 1.56x | $84.74 Million |
| 2008 | 13.49% | 19.11% | 0.48x | 1.46x | $202.56 Million |
| 2009 | 15.59% | 22.16% | 0.51x | 1.37x | $347.98 Million |
| 2010 | 18.63% | 21.31% | 0.58x | 1.50x | $465.62 Million |
| 2011 | 19.21% | 24.45% | 0.56x | 1.41x | $591.73 Million |
| 2012 | 19.82% | 25.02% | 0.54x | 1.46x | $683.88 Million |
| 2013 | 21.60% | 26.86% | 0.58x | 1.38x | $1.00 Billion |
| 2014 | 27.14% | 30.25% | 0.68x | 1.32x | $1.85 Billion |
| 2015 | 37.84% | 32.95% | 0.55x | 2.08x | $2.61 Billion |
| 2016 | 30.53% | 32.34% | 0.50x | 1.89x | $2.49 Billion |
| 2017 | 20.15% | 20.69% | 0.52x | 1.88x | $1.28 Billion |
| 2018 | 33.98% | 32.93% | 0.53x | 1.94x | $3.13 Billion |
| 2019 | 44.13% | 40.96% | 0.53x | 2.04x | $4.55 Billion |
| 2020 | 37.39% | 29.76% | 0.55x | 2.30x | $2.93 Billion |
| 2021 | 14.28% | 14.17% | 0.46x | 2.19x | $466.48 Million |
| 2022 | 22.74% | 29.95% | 0.41x | 1.83x | $1.71 Billion |
| 2023 | 7.85% | 11.81% | 0.37x | 1.81x | $-318.84 Million |
| 2024 | 9.76% | 16.87% | 0.34x | 1.68x | $-39.40 Million |
| 2025 | 7.08% | 13.18% | 0.33x | 1.61x | $-532.29 Million |
Industry Comparison
This section compares Biogen Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $342,550,672,778
- Average return on equity (ROE) among peers: 19.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biogen Inc (BIIB) | $18.26 Billion | -25.50% | 0.61x | $26.81 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |